A New Method for Individualized Digoxin Dosing in Elderly Patients

详细信息    查看全文

• 作者：Ana Martin-Suarez ; David García González ; Juan F. Macías Núñez…
• 刊名：Drugs & Aging
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：33
• 期：4
• 页码：277-284
• 全文大小：984 KB
• 参考文献：1.Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights. A review of digoxin and its use in contemporary medicine. Crit Pathw Cardiol. 2011;10:93–8.CrossRef PubMed
  2.Cheng JWM, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. Am J Geriatr Pharmacother. 2010;8:419–27.CrossRef PubMed
  3.De Jong PE, Halbesma N, Gansevoort RT. Screening for early chronic disease: what method fits best. Nephrol Dial Transpl. 2006;21:2358–61.CrossRef
  4.Heras M, Fernández-Reyes MJ, Guerrero MT, Sánchez R. Evaluación de la función renal en el anciano con la fórmula HUGE. Rev Esp Geriatr Gerontol. 2013;48:94–5.CrossRef PubMed
  5.Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing. Pharmacotherapy. 2013;33(9):912–21.CrossRef PubMed PubMedCentral
  6.Musso CG, Michelángelo H, Vilas M, Reynaldi J, Martínez B, Algranati L, JFM Núñez. Creatinine reabsorption by the aged kidney. Int Urol Nephrol. 2009;41:727–31.CrossRef PubMed
  7.Álvarez-Gregori JA, Robles NR, Mena C, Ardanuy R, Jauregui R, Núñez JFM. The value of a formula including haematocrit, blood urea and gender (HUGE) as a screening test for chronic renal insufficiency. J Nutr Health Aging. 2011;15:480–4.CrossRef PubMed
  8.Konishi H, Shimizu S, Chiba M, Minouchi T, Koida M, Yamaji A. Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyper-bolic model based on creatinine clearance. J Clin Pharm Ther. 2002;27(4):257–65.CrossRef PubMed
  9.Lacarelle B, Pisano P, Gauthier T, Villard PH, Guder F, Catalin J, Durand A. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Int J Biomed Comput. 1994;36(1–2):127–30.CrossRef PubMed
  10.Martín Suárez A, Sayalero Marinero ML, Calvo Hernández MV. Digoxina. In: Domínguez-Gil Hurlé A, editor. Monitorización de fármacos en la práctica clínica. Madrid: Amazon; 2015. p. 189–214.
  11.Pervaiz MH, Dickinson MG, Yamani M. Is digoxin a drug of the past? Cleve Clin J Med. 2006;73(9):821–4.CrossRef PubMed
  12.Bauman JL, DiDomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6(2):77–86.CrossRef PubMed
  13.Martín-Suárez A, Lanao JM, Calvo MV, Martín P, Domínguez-Gil A. Digoxin pharmacokinetics in patients with high serum digoxin concentrations. J Clin Pharm Ther. 1993;18(1):63–8.CrossRef PubMed
  14.Álvarez GJA, Núñez JFM. Differences between decreased glomerular filtration rate and renal failure: risks of the association of both concepts in the healthy elderly. Rev Esp Geriatr Gerontol. 2014;49:184–7.CrossRef
  15.Robles NR, Ferreira F, Martínez-Gallardo R, Álvarez-Gregori J, Sánchez-Casado E, Cubero JJ, et al. Hematocrit, urea and gender: the hematocrit, urea, and gender formula for prognosing progressive renal failure in diabetic nephropathy. Eur J Intern Med. 2012;23:283–6.CrossRef PubMed
  16.Robles NR, Félix FJ, Férnández-Berges D, Pérez-Castán J, Zaro MJ, Lozano L, et al. The HUGE formula (hematocrit, urea and gender): association with cardiovascular risk. Eur Rev Med Pharmacol Sci. 2013;17:1889–93.PubMed
  17.Heras M, Guerrero MT, Muñoz A, Ridruejo E, Fernández-Reyes MJ. The haematocrit, urea and gender formula: association with overall mortality in a cohort of elderly patients followed up for 8 years. Rev Esp Geriatr Gerontol. 2015;50(2):101–2.CrossRef PubMed
  18.Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med. 2006;166:2539–45.CrossRef PubMed
  19.Muzzarelli S, Stricker H, Pfister O, Foglia P, Moschovitis G, Mombelli G, Brunner-La Rocca H. Individual dosage of digoxin in patients with heart failure. QJM. 2011;104(4):309–17.CrossRef PubMed
  20.Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22.CrossRef PubMed
  21.Fernández de Gatta MM, Calvo MV, Hernández JM, Caballero D, San Miguel JF, Domínguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther. 1996;60(3):332–40.
  22.Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):1–90.CrossRef
  23.Vaz Perez A, Otawa K, Zimmermann AV, et al. The impact of impaired renal function on mortality in patients with acutely decompensated chronic heart failure. Eur J Heart Fail. 2010;12(2):122–28.
  24.January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRef PubMed
  25.National Kidney Foundation. Practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.CrossRef
  26.Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, CKD Prognosis Consortium, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932–43.CrossRef PubMed PubMedCentral
  27.Musso CG, Belloso WH, Scibona P, Bellizzi V, Núñez JFM. Impact of renal aging on drug therapy. Postgrad Med. 2015;127(6):623–9.CrossRef PubMed
  
• 作者单位：Ana Martin-Suarez (1) (5)
  David García González (2)
  Juan F. Macías Núñez (3) (5)
  Ramón Ardanuy Albajar (4)
  M. Victoria Calvo Hernández (1) (2) (5)
  
  1. Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain
  5. Instituto de Investigación Biomédica de Salamanca, University Hospital of Salamanca, Salamanca, Spain
  2. Pharmacy Services, University Hospital of Salamanca, Salamanca, Spain
  3. Nefrology Services, University Hospital of Salamanca, Salamanca, Spain
  4. Department of Statistics, Faculty of Sciences, University of Salamanca, Salamanca, Spain
  
• 刊物主题：Geriatrics/Gerontology; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1969

文摘

Background Digoxin is a frequently prescribed drug in the elderly population. Estimated glomerular filtration rate is widely used to adjust dosages. The HUGE value is a tool for differentiating the presence or absence of chronic kidney disease in elderly patients. We aimed to investigate the usefulness of the HUGE value to predict the initial dose of digoxin in patients aged older than 70 years.